Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.89 EUR | -2.64% | -6.66% | +37.62% |
06-24 | OSE: market welcomes CAR-T agreement | CF |
06-24 | OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center | CI |
Business Summary
- Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors;
- OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors;
- OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia;
- FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes);
- BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors;
- OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms:
- Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I;
- Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO;
- Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Number of employees: 55
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development on Pharmaceutical Products
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -87.83% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -87.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 16/11/04 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 30/05/16 |
Director of Finance/CFO | - | 30/04/16 | |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 19/12/21 |
Chief Operating Officer | - | 19/12/21 | |
Maryvonne Hiance
BRD | Director/Board Member | 75 | 30/05/16 |
Thomas Guillot
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - | |
Sophie Fay
PRN | Corporate Officer/Principal | - | - |
Françoise Bono
PRN | Corporate Officer/Principal | - | 19/12/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 16/11/04 | |
Director/Board Member | 66 | 21/06/23 | |
Didier Hoch
CHM | Chairman | 68 | 30/05/16 |
Maryvonne Hiance
BRD | Director/Board Member | 75 | 30/05/16 |
Director of Finance/CFO | - | 30/04/16 | |
Brigitte Dreno
BRD | Director/Board Member | 71 | 13/06/17 |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 30/05/16 |
Company contact information
OSE Immunotherapeutics SA
22, Boulevard Benoni Goullin
44000, Nantes
+33 2 28 29 10 10
http://www.ose-immuno.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.62% | 141M | |
+21.07% | 46.93B | |
+37.43% | 39.08B | |
-8.32% | 38.48B | |
+29.60% | 31.01B | |
-12.26% | 26.14B | |
+11.15% | 25.88B | |
+35.39% | 12.53B | |
-6.56% | 11.36B | |
-12.31% | 10.65B |
- Stock Market
- Equities
- OSE Stock
- Company OSE Immunotherapeutics